Current Report Filing (8-k)
October 03 2016 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): September 30, 2016
CATALYST PHARMACEUTICALS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
|
|
|
|
|
Delaware
|
|
001-33057
|
|
76-0837053
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
355 Alhambra Circle
Suite 1250
Coral Gables,
Florida
|
|
33134
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (305) 420-3200
Not Applicable
Former
Name or Former address, if changed since last report
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 3.01
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
|
On
September 30, 2016, the Company received a notice from The NASDAQ Stock Market (NASDAQ) confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market.
On June 9, 2016, NASDAQ notified the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule
5550(a)(2) (the Rule) for continued listing on the NASDAQ Capital Market. The Rule requires that listed securities maintain a minimum bid price of $1.00 per share. The Company was provided 180 calendar days, or until December 6, 2016, in
which to regain compliance with the Rule. On September 30, 2016, NASDAQ confirmed to the Company that, as a result of the Companys common stock closing with a bid price of at least $1.00 for at least ten consecutive days, the Company has come
into compliance with the Rule and the matter is now closed.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
Catalyst Pharmaceuticals, Inc.
|
|
|
By:
|
|
/s/ Alicia Grande
|
|
|
Alicia Grande
|
|
|
Vice President, Treasurer and CFO
|
Dated: October 3, 2016
3
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024